Andrew Alliance, a Geneva, Switzerland-based the developer of a co-worker robot that makes laboratory operations more efficient, closed a series B financing round.
Backers included Omega Funds, a global healthcare fund specializing in late stage life science investments. In conjunction with the funding, Dr. Vincent Ossipow, Venture Partner with Omega, will join Dr. Piero Zucchelli and Dr. Sam Eletr, co-founder of Andrew Alliance on the Board of Directors.
The investment will enable the company to expand the reach of its well-received robots, by enabling new developments and the establishment of commercial operations in the U.S. market.
Founded in 2011, Andrew Alliance offers the Andrew Robot, a novel co-worker robot designed to assist scientists in a routine laboratory operation called “liquid handling”. Andrew takes over the manipulation of commercial laboratory pipettes designed for manual operations, and allows scientists and technicians to automate both new and established protocols, while removing health risks and errors.
The robot is commercially available in more than 17 countries through a network of distributor partners, and distributed directly by Andrew Alliance elsewhere.
FinSMEs
05/08/2014